Key result
Acute antipsychotics are linked to lower coagulation biomarkers in schizophrenia, while chronic effects vary.
Why the study?
Previous studies reported higher incidences of venous thromboembolism and cardiovascular disease in schizophrenia patients and higher indicators of thrombosis, thrombocyte activation, and platelet dysfunction, but the effects of acute and chronic antipsychotics on coagulation biomarkers were unclear.
Do acute and chronic antipsychotic medications have different effects on blood coagulation and fibrinolysis-related biomarkers in patients with schizophrenia?
Case-Control (n=81)
Do acute and chronic antipsychotic medications have different effects on blood coagulation and fibrinolysis-related biomarkers in patients with schizophrenia?
First-episode schizophrenia is associated with a hypercoagulable state, and acute versus chronic antipsychotic treatments exert contrasting effects on coagulation and fibrinolysis biomarkers.
Answers are grounded in this paper and cite their sources.
Acute antipsychotics may lower coagulation markers in early schizophrenia; leaves open differential thrombotic effects of chronic therapy.
Background: Previous studies reported higher incidences of venous thromboembolism and cardiovascular disease in schizophrenia patients and higher indicators of thrombosis, thrombocyte activation, and platelet dysfunction. Objectives: To check if first-episode schizophrenia (FES) patients have a hypercoagulable state and determine whether acute and chronic antipsychotics have the same effect on blood coagulation or fibrinolysis-related biomarkers. Design: Case-control study. Methods: A total of 81 participants were grouped in FES, chronic schizophrenia (CS), and healthy controls (HCs). In addition to demographic data and clinical characteristics, immunological analyses were performed to measure plasma levels of D-dimer, plasminogen activator inhibitor-1 (PAI-1), soluble P selectin (sP-sel), tissue plasminogen activator (tPA), thrombotic precursor protein (TpP), and von Willebrand's disease factor (vWF). Results: 2.00). Acute antipsychotic medication reduced higher PAI-1 (28.61 → 21.99), sP-sel (2.78 → 1.87), tPA (9.59 → 5.83), TpP (15.61 → 10.54), and vWF (383.18 → 291.08) in FES patients. However, plasma sP-sel and vWF in CS patients returned to the pre-treatment levels in FES patients, and PAI-1/tPA significantly decreased compared to FES patients. Conclusion: These results suggest a hypercoagulable state in FES patients and demonstrate contrast effects of acute and chronic antipsychotics on coagulation or fibrinolysis in schizophrenia patients.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2023) conducted a case-control in Schizophrenia (n=81). Acute and chronic antipsychotic medications vs. Healthy controls and pre-treatment levels was evaluated on Plasma levels of coagulation and fibrinolysis-related biomarkers (PAI-1, sP-sel, tPA, TpP, vWF). Acute antipsychotic medication reduced elevated coagulation biomarkers in first-episode schizophrenia, while chronic antipsychotics had contrasting effects on coagulation and fibrinolysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: